Schrier R D, Gnann J W, Landes R, Lockshin C, Richman D, McCutchan A, Kennedy C, Oldstone M B, Nelson J A
Department of Immunology, Research Institute of Scripps Clinic, La Jolla, CA 92037.
J Immunol. 1989 Feb 15;142(4):1166-76.
Because T cell responses are critical for defense against viral infections, a series of synthetic peptides derived from the predicted sequence for HIV-1 proteins gp41, pg120, gag, and viral polymerase were used to test the T cell proliferative response of HIV-1 seropositive individuals. Of HIV-1-infected donors from various clinical categories 90% (27/30) had sensitized cells that proliferated in response to at least one of 21 HIV peptides tested. Cells from HIV seronegative controls did not proliferate (0/9) in response to these HIV peptides. Individuals with fewer clinical manifestations of HIV-1 disease responded to a greater number of peptides (average for asymptomatic seropositives = 8.1 peptides; AIDS patients averaged 2.0). The number of peptides recognized also correlated with absolute number of CD4+ cells, but not with delayed cutaneous hypersensitivity to a (non-HIV) battery of Ag. However, clinical stage at no time correlated with the response to any particular peptide. Response patterns differed considerably among individuals, and some peptides stimulated proliferation in many (48%) HIV-infected donors (peptides gp41-2 and pol-3), whereas another peptide elicited no T cell response in any donor tested (peptide gp120-8). We have also begun to investigate the basis for individual heterogeneity of T lymphocyte proliferative responses of HIV-infected donors to the 21 HIV synthetic peptides. Peptide structure and HLA class II determinants both influenced patterns of lymphocyte responses. Reactivity correlated with peptide size, the presence of alpha and beta secondary structure and lack of reverse turn potential. Hydropathy and charge had no predictive value. Peptides derived from HIV sequences that vary highly among strains tended to be recognized less frequently. HIV-infected lymphocyte donors were HLA typed to examine the influence of the MHC on T lymphocyte proliferation. Analysis of the frequencies of individuals reacting to specific peptides, when compared to the allele frequencies in the population at large, indicated association of some responses to DR alleles. More DR association was observed with peptides that showed "moderate" reactivity than with those that were "highly" reactive. We suggest that highly reactive peptides are capable of forming a structure closer to an "ideal" T cell epitope that can associate with many DR alleles. In contrast, "moderately" reactive determinants have less favorable structures for interaction, are more limited in their ability to interact and therefore show more restriction to specific class II alleles.
由于T细胞反应对于抵御病毒感染至关重要,因此使用了一系列源自HIV-1蛋白gp41、gp120、gag和病毒聚合酶预测序列的合成肽,来检测HIV-1血清阳性个体的T细胞增殖反应。在来自不同临床类别的HIV-1感染供体中,90%(27/30)的供体有被致敏的细胞,这些细胞对所检测的21种HIV肽中的至少一种有增殖反应。HIV血清阴性对照的细胞对这些HIV肽无增殖反应(0/9)。HIV-1疾病临床表现较少的个体对更多的肽有反应(无症状血清阳性个体平均为8.1种肽;艾滋病患者平均为2.0种)。所识别的肽的数量也与CD4+细胞的绝对数量相关,但与对一组(非HIV)抗原的迟发性皮肤超敏反应无关。然而,临床分期与对任何特定肽的反应在任何时候都不相关。个体之间的反应模式差异很大,一些肽能刺激许多(48%)HIV感染供体的增殖(肽gp41-2和pol-3),而另一种肽在任何测试供体中都未引发T细胞反应(肽gp120-8)。我们也已开始研究HIV感染供体对21种HIV合成肽的T淋巴细胞增殖反应个体异质性的基础。肽结构和HLA II类决定簇均影响淋巴细胞反应模式。反应性与肽大小、α和β二级结构的存在以及无反向转折可能性相关。亲水性和电荷无预测价值。源自不同毒株间差异很大的HIV序列的肽往往较少被识别。对HIV感染的淋巴细胞供体进行HLA分型,以检查MHC对T淋巴细胞增殖的影响。与总体人群中的等位基因频率相比,分析对特定肽有反应的个体频率,表明某些反应与DR等位基因有关联。与“高度”反应性的肽相比,观察到与“中等”反应性的肽有更多的DR关联。我们认为,高反应性肽能够形成更接近“理想”T细胞表位的结构,该表位可与许多DR等位基因结合。相反,“中等”反应性决定簇的相互作用结构较不利,其相互作用能力更有限,因此对特定II类等位基因的限制性更强。